A British pharmaceutical company has won a European patent for its ‘cancer vaccine’ technology, which could change the treatment of cancers.
Scancell has been granted the patent for its DNA ImmunoBody scientific platform.
The immunotherapy technology enables Scancell to raise up cancer-fighting T-cells to eliminate tumours, which has the potential for a permanent cure.
Scancell is among a multitude of British firms competing for a part of the expected $50bn (£39bn) a year global immuno-oncology (IO) drugs business.
People in the industry think the fierce global race among pharmaceutical companies to become IO market leaders make small businesses with limited clinical data such as Scancell a takeover target.
Scancell’s Immunobody patent serves for 20 years and ensures European competitors cannot reproduce or do the same scientific platform, protecting its possible chances of victory.
The award follows related patent guarantees given to Scancell in the US, Australia, and Japan.
Dr Richard Goodfellow, CEO of Scancell, said: “The addition of this key European patent for DNA ImmunoBody significantly bolsters our global intellectual property portfolio as we position the company for future growth.”
Scancell is listed on London’s AIM market, its share price was up more than 1pc in midday training, giving it a market cap just short of £32m.